(Q37656214)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

First-line treatment of advanced ovarian cancer: current research and perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Gaetano Facchini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Simona Losito

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Carmela Pisano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Giovanni Salvatore Bruni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Francesca Paola Magazzino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sandro Pignata

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

47-60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

21 January 2018

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Pharmaceutical management of ovarian cancer : current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Intraperitoneal drug delivery of antineoplastics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.167

21 January 2018

Identifiers

DOI

10.1586/ERA.09.167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20014885%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference